Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A better sleep-quality score over two weeks does not establish long-term treatment superiority.
More dispensing after coverage expansion is not itself proof of more inappropriate use or medication harm.
Separation of two active ingredients in tablets does not validate their measurement in blood.
Catatonic symptoms after cessation can be related to withdrawal, underlying illness or both.
The human origin of a laboratory enzyme preparation does not turn the whole experiment into a human clinical study.
Improved reported anesthesia experience is distinct from proof of better overall recovery or safety.
Improvement in an experimental EEG measure is not proof of a validated human combination treatment.
An animal’s repeated movement is an observation; its motivation requires additional evidence.
A short-acting label does not guarantee prompt spontaneous awakening in severe hepatic disease.
Analytical sensitivity does not establish the clinically desirable dose or diagnose overdose.
An uneventful case demonstrates feasibility, not comparative neurological safety.
Prospective data collection does not remove treatment-selection bias.
A stability-indicating tablet method is not automatically a validated forensic biological-fluid method.
The formulation and how it is swallowed can change exposure even when the nominal dose is unchanged.
The actual treatment package matters more than a shortened group name.
Self-reported enduring symptoms deserve description, but the survey cannot establish how often they occur among all users.
An early response followed by another medicine cannot establish comparative superiority.
One favorable recovery endpoint does not establish that a regimen is uniformly safer.
Communication problems across professional roles are care-process findings, not measured treatment effects.
Higher cumulative sedative exposure can reflect both treatment and the severity or duration of critical illness.
The concentration near an enzyme may differ from a convenient plasma or nominal laboratory concentration.
Human cells provide mechanistic evidence without reproducing an intact critically ill patient.
A sedative history can be relevant without accounting for the whole neurological presentation.
A tissue-specific negative result is narrower than proof that diabetes never changes drug exposure.
Using midazolam as a proposed enzyme probe does not demonstrate that bypass or ECMO changed its clearance.
Similar ratings during a procedure do not establish identical recovery or patient experience.
More stable pressure during induction is a short-term physiological finding rather than proof of superior overall surgical safety.
A drug concentration can fall during plasma exchange, but the clinical consequence requires separate evidence.
A willingness-to-change framework captures experience and communication; it does not measure a universal discontinuation success rate.
An increase in dispensed packs is a change in supply volume, not a direct count of people starting treatment.